We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
deCODE Expands Cancer Program through Acquisition of UVS
News

deCODE Expands Cancer Program through Acquisition of UVS

deCODE Expands Cancer Program through Acquisition of UVS
News

deCODE Expands Cancer Program through Acquisition of UVS

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "deCODE Expands Cancer Program through Acquisition of UVS"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

deCODE genetics has announced its acquisition of privately-held Icelandic cancer research firm Urdur, Verdandi Skuld (UVS).

The acquisition enables deCODE to broaden and enhance its cancer program by applying the company's gene discovery and drug development capabilities to an even larger set of population-based resources.

"UVS has organized cancer research in Iceland since 1998 and has recruited a large number of patients and controls into their studies," said Kari Stefansson, CEO of deCODE.

"This acquisition strengthens our ability to use population genetics to develop better methods to diagnose, treat and prevent cancer."

"This is our goal and the goal of the thousands of patients and family members, as well as the dedicated clinicians and scientists, who have taken part in our work and that of UVS over the years."

deCODE will acquire UVS for $5.5 million that will be paid in deCODE common stock based on the average closing price for the 30 days preceding the acquisition.

Advertisement